Dysbiosis in the breast microbiome can lead to inflammation in breast tissue, increasing M2-like macrophage infiltration, enhancing levels of interleukin (IL)-23, IL-22, CXCL-1, and CCL-2, and accelerating fibrosis within the tumor environment (Buchta Rosean et al., 2019). The gene discussed is IL22; the disease is neoplasm.